Therefore, lack of PAK4 expression facilitates changes in the tumor microenvironment, which become more evident when given anti-PD-1 therapy, to sensitize melanoma B16 tumors to anti-PD-1 treatment (13). Here, PAK4 is linked to neoplasm.